Accuray (ARAY)
(Real Time Quote from BATS)
$2.22 USD
+0.10 (4.72%)
Updated Apr 23, 2024 03:37 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARAY 2.22 +0.10(4.72%)
Will ARAY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARAY
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
ARAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
Other News for ARAY
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Slone Partners Places Chris Raanes as CEO at Magnetic Insight
Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System